share_log

Abbott Laboratories | 10-Q: Q2 2024 Earnings Report

Abbott Laboratories | 10-Q: Q2 2024 Earnings Report

雅培 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/07/31 15:06

Moomoo AI 已提取核心訊息

Abbott Laboratories reported Q2 2024 net sales of $10.4 billion, up 4.0% year-over-year, with organic growth of 7.5% excluding foreign exchange impact. Medical Devices segment led growth with a 10.2% increase to $4.7 billion, driven by FreeStyle Libre continuous glucose monitoring system sales of $3.0 billion in H1. Net earnings were $1.3 billion with diluted EPS of $0.74.The company saw strong performance across segments, with Nutritional Products up 3.5% and Established Pharmaceuticals up 0.6%. However, Diagnostic Products declined 5.3% to $2.2 billion due to lower COVID-19 testing demand, with COVID-19 testing sales dropping to $102 million from $263 million in Q2 2023. Gross margin improved to 51.1% from 50.1% last year.Abbott maintained its financial strength with $7.0 billion in cash and equivalents as of June 30, 2024. The company increased its quarterly dividend by 7.8% to $0.55 per share and received key regulatory approvals, including FDA clearance for new over-the-counter continuous glucose monitoring systems and FDA approval for the Esprit BTK system and TriClip tricuspid valve repair device.
Abbott Laboratories reported Q2 2024 net sales of $10.4 billion, up 4.0% year-over-year, with organic growth of 7.5% excluding foreign exchange impact. Medical Devices segment led growth with a 10.2% increase to $4.7 billion, driven by FreeStyle Libre continuous glucose monitoring system sales of $3.0 billion in H1. Net earnings were $1.3 billion with diluted EPS of $0.74.The company saw strong performance across segments, with Nutritional Products up 3.5% and Established Pharmaceuticals up 0.6%. However, Diagnostic Products declined 5.3% to $2.2 billion due to lower COVID-19 testing demand, with COVID-19 testing sales dropping to $102 million from $263 million in Q2 2023. Gross margin improved to 51.1% from 50.1% last year.Abbott maintained its financial strength with $7.0 billion in cash and equivalents as of June 30, 2024. The company increased its quarterly dividend by 7.8% to $0.55 per share and received key regulatory approvals, including FDA clearance for new over-the-counter continuous glucose monitoring systems and FDA approval for the Esprit BTK system and TriClip tricuspid valve repair device.
雅培在2024年第二季度報告淨銷售額爲104億美金，同比增長4.0%，在不考慮匯率影響的情況下，歸因於7.5%的有機增長。醫療設備部門引領增長，增加了10.2%，達到47億美金，主要受益於在上半年銷售的FreeStyle Libre連續血糖監測系統的30億美金。淨收益爲13億美金，攤薄後每股收益爲0.74美金。該公司在各個部門的表現都很強勁，營養產品增長了3.5%，成熟藥品增長了0.6%。然而，診斷產品因COVID-19檢測需求下降，下降了5.3%，降至22億美金，COVID-19檢測銷售額從2023年第二季度的26300萬美金降至10200萬美金。毛利率從去年的50.1%提高到51.1%。截...展開全部
雅培在2024年第二季度報告淨銷售額爲104億美金，同比增長4.0%，在不考慮匯率影響的情況下，歸因於7.5%的有機增長。醫療設備部門引領增長，增加了10.2%，達到47億美金，主要受益於在上半年銷售的FreeStyle Libre連續血糖監測系統的30億美金。淨收益爲13億美金，攤薄後每股收益爲0.74美金。該公司在各個部門的表現都很強勁，營養產品增長了3.5%，成熟藥品增長了0.6%。然而，診斷產品因COVID-19檢測需求下降，下降了5.3%，降至22億美金，COVID-19檢測銷售額從2023年第二季度的26300萬美金降至10200萬美金。毛利率從去年的50.1%提高到51.1%。截至2024年6月30日，雅培維持了70億美金的現金和現金等價物的財務實力。該公司將季度股息提高了7.8%，達到每股0.55美金，並獲得了關鍵的監管批准，包括FDA對新型非處方連續血糖監測系統的許可以及FDA對Esprit BTk系統和TriClip三尖瓣修復設備的批准。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點